The Journal of Bone and Joint Surgery (American). 2005;87:2097-2112.
doi:10.2106/JBJS.D.03033
© 2005 The Journal of Bone and Joint Surgery, Inc.
Prevention of Venous Thromboembolic Disease After Total Hip and Knee Arthroplasty
Jay R. Lieberman, MD1 and
Wellington K. Hsu, MD1
1 Department of Orthopaedic Surgery, David Geffen School of Medicine at
University of California at Los Angeles, Center for Health Sciences 76-134,
10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail address for J.R.
Lieberman:
jlieberman{at}mednet.ucla.edu.
E-mail address for W.K. Hsu:
whsu{at}mednet.ucla.edu
Investigation performed at the Department of Orthopaedic Surgery, David
Geffen School of Medicine at University of California at Los Angeles, Los
Angeles, California
The authors did not receive grants or outside funding in support of their
research or preparation of this manuscript. They did not receive payments or
other benefits or a commitment or agreement to provide such benefits from a
commercial entity. No commercial entity paid or directed, or agreed to pay or
direct, any benefits to any research fund, foundation, educational
institution, or other charitable or nonprofit organization with which the
authors are affiliated or associated.
Patients undergoing total hip and knee arthroplasty are at increased risk
for the development of venous thromboembolic disease, and there is general
agreement that these patients require prophylaxis.
The selection of a prophylactic agent involves a balance between efficacy
and safety and often needs to be individualized for specific patients and
institutions.
Despite extensive research, the ideal agent for prophylaxis against deep
venous thrombosis has not been identified. The results of randomized trials
indicate that low-molecular-weight heparin, warfarin, and fondaparinux are the
most effective prophylactic agents after total hip arthroplasty and that
low-molecular-weight heparin, warfarin, fondaparinux, and pneumatic
compression boots are the most effective agents after total knee
arthroplasty.
The duration of prophylaxis against deep venous thrombosis after total hip
and knee arthroplasty remains controversial. Prophylaxis should be continued
beyond hospital discharge. In the future, the determination of the duration of
prophylaxis will be based on the risk stratification of individual
patients.
The practice of discharging patients from the hospital without prophylaxis,
even when the decision is based on negative results of procedures that screen
for the presence of deep venous thrombosis, is not cost-effective.

CiteULike Connotea Del.icio.us Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
381S - 453S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Dorr, V. Gendelman, A. V. Maheshwari, M. Boutary, Z. Wan, and W. T. Long
Multimodal Thromboprophylaxis for Total Hip and Knee Arthroplasty Based on Risk Assessment
J. Bone Joint Surg. Am.,
December 1, 2007;
89(12):
2648 - 2657.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Letters to the Editor:
Read all Letters to the Editor
- Prevention of VTE after major orthopaedic surgery and the role of prolonged prophylaxis
- David Bergqvist, M.D., Ph.D., FRCS
- JBJS Online, 13 Dec 2005
[Full text]
|